Dr. Reddy’s Laboratories Ltd. has formally announced its Net Zero commitments after receiving approval for both its near-term and long-term emission reduction targets from the Science Based Targets initiative (SBTi). The company, which is listed on the BSE, NSE, NYSE, and NSE IFSC, confirmed that its targets are aligned with the SBTi’s latest framework for climate science–based decarbonization pathways.
Under the newly approved plan, Dr. Reddy’s has committed to achieving Net Zero greenhouse gas emissions across its entire value chain by FY2045. This positions the company as the only pharmaceutical firm in India to declare a science-based Net Zero target for this timeline, reinforcing its leadership in environmental sustainability within the sector.
The announcement outlines a rigorous decarbonization agenda. In the near term, Dr. Reddy’s plans to reduce its absolute Scope 1 and Scope 2 emissions by 80 percent and lower Scope 3 emissions by 51.6 percent per INR value added by FY2030, with FY2023 as the baseline year. Its long-term commitment focuses on a 90 percent absolute reduction across Scope 1, 2, and 3 emissions by FY2045, also measured from the FY2023 baseline. These commitments reflect a broad transformation strategy spanning operations, supply chain, energy management, and product stewardship.
Dr. Reddy’s first announced its near-term SBTi targets in October 2020. Building on measurable progress and its sustained focus on responsible growth, the company has now expanded and revised its climate goals to align with the SBTi’s Net Zero framework. The updated commitments demonstrate an integrated approach to sustainability, reinforcing the company’s intent to support global climate objectives while enhancing resilience and operational efficiency.